<DOC>
	<DOCNO>NCT01041846</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness safety decitabine ( Dacogen ) intravenous injection patient Myelodysplastic Syndrome .</brief_summary>
	<brief_title>A Study Dacogen Treatment Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>This prospective ( patient first identify follow forward time pass ) , multi-center ( study conduct multiple site ) , observational study ( scientific study make clear easy understanding cause effect relationship ) evaluate effectiveness safety information 5 day decitabine ( Dacogen ) regimen patient Myelodysplastic Syndrome . This study consist 3 phase ; pre-treatment phase , treatment phase end treatment ( Day 28~61 last administration Dacogen ) . The patient receive decitabine intravenous injection 20 mg/m2 one hour daily 5 consecutive day every 4 week . Safety evaluation include adverse event clinical laboratory test evaluate adverse event report period range informed consent study end treatment visit include 56 day ( 8 week ) last administration clinical study treatment .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<criteria>Patients diagnose ( primary secondary ) Myelodysplastic Syndrome include chronic myelomonocytic leukemia ( CMML ) International Prognostic Scoring System equal Interferon1 Patients never treat hypomethylating agent ( azacitidine decitabine ) Female patient postmenopausal receive contraceptive operation refrain sexual relation . Women childbearing potential conduct effective method birth control define protocol , case male patient baby within 2 month completion decitabine therapy Patients diagnose acute myelogenous leukemia ( bone marrow stem cell count exceed 20 % ) progressive malignant diseases Patients active infection virus bacteria Patients use treated azacitidine decitabine Patients hypersensitive excipients decitabine Patients pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Dacogen</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Epigenetic therapy</keyword>
	<keyword>Hypomethylating agent</keyword>
</DOC>